tradingkey.logo

Amphastar Pharmaceuticals Inc

AMPH
查看详细走势图
27.120USD
+0.310+1.16%
收盘 12/26, 16:00美东报价延迟15分钟
1.26B总市值
11.50市盈率 TTM

Amphastar Pharmaceuticals Inc

27.120
+0.310+1.16%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.16%

5天

+1.95%

1月

-0.88%

6月

+17.00%

今年开始到现在

-26.96%

1年

-28.95%

查看详细走势图

操作建议

Amphastar Pharmaceuticals Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名30/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价31.71。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Amphastar Pharmaceuticals Inc评分

相关信息

行业排名
30 / 158
全市场排名
86 / 4563
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 6 位分析师
买入
评级
31.714
目标均价
+21.93%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Amphastar Pharmaceuticals Inc亮点

亮点风险
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
业绩高增长
公司营业收入稳步增长,连续3年增长46.69%
利润高增长
公司净利润处于行业前列,最新年度总收入731.97M美元
估值合理
公司最新PE估值11.50,处于3年历史合理位
机构加仓
最新机构持股33.97M股,环比增加0.05%
HACAX持仓
明星投资者HACAX持仓,最新持仓市值276.00

Amphastar Pharmaceuticals Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Amphastar Pharmaceuticals Inc简介

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
公司代码AMPH
公司Amphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
网址https://amphastar.com/

常见问题

Amphastar Pharmaceuticals Inc(AMPH)的当前股价是多少?

Amphastar Pharmaceuticals Inc(AMPH)的当前股价是 27.120。

Amphastar Pharmaceuticals Inc的股票代码是什么?

Amphastar Pharmaceuticals Inc的股票代码是AMPH。

Amphastar Pharmaceuticals Inc股票的52周最高点是多少?

Amphastar Pharmaceuticals Inc股票的52周最高点是39.010。

Amphastar Pharmaceuticals Inc股票的52周最低点是多少?

Amphastar Pharmaceuticals Inc股票的52周最低点是20.385。

Amphastar Pharmaceuticals Inc的市值是多少?

Amphastar Pharmaceuticals Inc的市值是1.26B。

Amphastar Pharmaceuticals Inc的净利润是多少?

Amphastar Pharmaceuticals Inc的净利润为159.52M。

现在Amphastar Pharmaceuticals Inc(AMPH)的股票是买入、持有还是卖出?

根据分析师评级,Amphastar Pharmaceuticals Inc(AMPH)的总体评级为买入,目标价格为31.714。

Amphastar Pharmaceuticals Inc(AMPH)股票的每股收益(EPS TTM)是多少

Amphastar Pharmaceuticals Inc(AMPH)股票的每股收益(EPS TTM)是2.358。
KeyAI